

# Amgen Inc

**250.18** Usd  
+0.79%

ISIN: US0311621009  
Ticker: AMGN

Sector: Biotechnology  
Stock exchange: NASDAQ

Market capitalization: 146.25 billion

**Key Metrics:**

Performance YTD: 3.78%  
Estimated 2020 P/E: 14.45

Earning per share: 12.96  
Price to book: 13.93

Net Debt: 22 B  
Return on Equity: 0.68

## Fundamental analysis summary

Amgen is the largest biotech company in the world. However, its profile is more like a typical pharma profile. It pays dividends (2.5%), earned c. USD 8 trillion in profits in 2019 but its growth in YoY sales also remains slow (6%). It has a rather alarming level of debt (Debt to Equity = 3.2). In addition, Amgen faces stiff competition in biosimilars and generics. However, its introduction in the DOW will certainly create buying pressure.

## Technical analysis summary

The share price is just about at its pre-covid price. It has shown a lot of volatility by making large swings. The announcement of its entry on the DOW recently made it take 5% while it had been declining for the last month.

## Chart - Year To Date

